In order to determine whether ovarian cancer cell lines predominantly express the full-length (IL-6R) or the differentially spliced isoform that lacks the transmembrane domain (sIL-6R), we designed primers that code splicing lesions and performed RT-PCR (Fig. 2D). This evidence concerns the gene IL6R and ovarian cancer.